Two of the experimental coronavirus drugs, chloroquine, and hydroxychloroquine are a breeze to synthesize. But remdesivir, possibly the most promising candidate, is anything but. It's a royal pain. Here's why.
On Rachel Maddow's MSNBC show, New York Times science and health reporter Donald McNeil praised China's mass quarantine camps as the best way to fight the COVID-19 pandemic. A CBC documentary reveals what that policy entails: Citizens are literally being dragged out of their homes as they cry and scream. Others have their doors welded shut.
In the Digital Age, we have access to more information than at any time in human history. But that doesn't stop the spread of conspiracy theories. Here are the best (worst?) ones involving the new coronavirus and the disease COVID-19.
If there was any effect of this drug on COVID-19, it was minimal. Hydroxychloroquine, whose toxicity is far lower, may be safer than chloroquine. But that doesn't matter if the drugs are ineffective.
Chloroquine, the old malaria drug, is making news as a potential therapy for coronavirus. Does it belong in the headlines for its antiviral properties, or is it just hype and bluster? Will it become a drug? Let's find out.
Dr. David Shlaes' primary expertise is in bacterial infections and antibiotics. So it's not surprising that our ACSH advisor is wondering about secondary bacterial infections from coronavirus infections. Will there be antibiotics to combat the infections this time? How about next time?
As the horror known as the coronavirus tightens its grip on the world, and a vaccine is years away, our best hope is an antiviral drug that minimizes the damage caused by coronavirus replication. New data on favipiravir, a repurposed drug originally discovered in Japan, looks promising in trials in China. But nothing is ever straightforward in drug discovery -- and that is no different here. Here's a summary of the new findings.
Extraordinary times call for extraordinary measures. But these kinds of measures can't last forever. The public is willing to tolerate massive disruptions to daily life only when it believes the disruptions will end. Therefore, mitigation is a more viable option.
Dr. David Shlaes, an infectious disease expert and ACSH advisor, is incensed over the nation's lack of preparedness for the coronavirus epidemic. A scenario like this has been discussed for three decades, yet we are still in the middle of a disaster. Here are his thoughts.
There are two false narratives emerging on social media that need to be addressed. The first is that the virus is a hoax. The second is that the U.S. is "the next Italy." Both are wrong.
As the Wuhan coronavirus relentlessly engulfs the world, scientists are relentlessly looking for a way to treat the infection. A vaccine is more than a year away, but an antiviral drug called remdesivir is being evaluated in clinical trials by Gilead Science, the world's premier antiviral drug company. Keep your fingers crossed.
I'm returning to my surgical roots to talk about what’s on our minds: uncertainty, disease, and death. Here are some lessons from 30 years of talking to patients and families about situations that are now very real for us all.